The invention relates to a compound of formula (I)
wherein A and R
1
to R
3
are defined as in the description and in the claims. The compound of formula (I) can be used as a medicament.
[EN] [1, 2, 3]TRIAZOLO [4, 5 -D] PYRIMIDINE DERIVATIVES AS AGONISTS OF THE CANNABINOID RECEPTOR 2 AGONISTS<br/>[FR] DÉRIVÉS DE [1, 2, 3]TRIAZOLO [4, 5 -D] PYRIMIDINE COMME AGONISTES DES RÉCEPTEURS AUX CANNABINOÏDES 2
申请人:HOFFMANN LA ROCHE
公开号:WO2013076182A1
公开(公告)日:2013-05-30
The invention relates to a compound of formula (I) wherein A and R to R 3 are defined as in the description and in the claims. The compound of formula (I) can be used as a medicament.
[EN] SUBSTITUTED HETEROAROMATIC PYRAZOLO-PYRIDINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS<br/>[FR] PYRAZOLO-PYRIDINES HÉTÉROAROMATIQUES SUBSTITUÉES ET LEUR UTILISATION EN TANT QUE MODULATEURS DU RÉCEPTEUR GLUN2B
申请人:JANSSEN PHARMACEUTICA NV
公开号:WO2020249785A1
公开(公告)日:2020-12-17
Substituted Pyrazolo-pyridines as GluN2B receptor ligands. Such compounds may be used in GluN2B receptor modulation and in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by GluN2B receptor activity.
[EN] TETRAHYDROISOQUINOLINE COMPOUNDS AS NRF2 ACTIVATORS<br/>[FR] COMPOSÉS DE TÉTRAHYDROISOQUINOLÉINE UTILISÉS EN TANT QU'ACTIVATEURS DE NRF2
申请人:C4X DISCOVERY LTD
公开号:WO2021214470A1
公开(公告)日:2021-10-28
The present invention relates to compounds that are Nrf2 activators. The compounds have the structural formula I defined herein. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of diseases or disorders associated with Nrf2 activation.
[EN] [1, 2, 3] TRIAZOLO [4, 5 -D] PYRIMIDINE DERIVATIVES AS AGONISTS OF THE CANNABINOID RECEPTOR 2<br/>[FR] DERIVES DE [1,2,3]]TRIAZOLO[4,5-D]PYRIMIDINE COMME AGONISTES DU RECEPTEUR CANNABINOIDE 2
申请人:HOFFMANN LA ROCHE
公开号:WO2013068306A1
公开(公告)日:2013-05-16
The invention relates to a compound of formula (I), wherein A, R1 and R2 are defined as in the description and in the claims. The compound of formula (I) can be used as a medicament as agonists of the cannabinoid receptor 2.